BioLineRx to Report Annual 2016 Results on March 23, 2017
The Company will host a conference call on
To dial into the conference call, please dial 1-888-281-1167 from the U.S. or +972-3-918-0687 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call at http://www.biolinerx.com. A dial-in replay of the call will be available until
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds, primarily from academic institutions and biotech companies based in
BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML and is in the midst of a Phase 2b study as an AML consolidation treatment and a Phase 2 study in stem cell mobilization for allogeneic transplantation; and BL-7010 for celiac disease and gluten sensitivity, which has successfully completed a Phase 1/2 study. In addition, BioLineRx has a strategic collaboration with
For additional information on BioLineRx, please visit the Company's website at http://www.biolinerx.com, where you can review the Company's
Contact:
PCG Advisory
Investor Relations
+1-212-554-5482
vivian@pcgadvisory.com
or
Tsipi Haitovsky
Public Relations
+972-3-624-0871
tsipihai5@gmail.com
SOURCE